嵌合抗原受体T淋巴细胞免疫疗法在原发性肝癌中的应用

李康伟; 尉丁; 张若涵; 李霄; 陶开山

doi:10.3969/j.issn.1001-5256.2022.10.036

嵌合抗原受体T淋巴细胞免疫疗法在原发性肝癌中的应用

DOI: 10.3969/j.issn.1001-5256.2022.10.036

李康伟^1a,
尉丁^1b,
张若涵²,
李霄²,
陶开山^2, , ,

1a.
第四军医大学研究生院，西安 710032
1b.
第四军医大学基础医学院细胞生物学教研室，西安 710032
2.
第四军医大学西京医院肝胆胰脾外科，西安 710032

基金项目:

国家自然科学基金 (82170667);

国家自然科学基金 (81970566)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：李康伟起草并撰写文章主要内容；尉丁负责协助补充文献并完善文章内容；张若涵负责主要内容修改；李霄协助文章修改及审校；陶开山指导文章思路并修改了文章关键内容。

详细信息

通信作者:
陶开山，taokaishan0686@163.com

计量
- 文章访问数: 377
- HTML全文浏览量: 87
- PDF下载量: 55
- 被引次数: 0
出版历程
- 收稿日期: 2022-03-05
- 录用日期: 2022-04-07
- 出版日期: 2022-10-20

Application of chimeric antigen receptor T-cell immunotherapy in primary liver cancer

Kangwei LI^1a,
Ding WEI^1b,
Ruohan ZHANG²,
Xiao LI²,
Kaishan TAO^{2
, ,
,}

1a.
Graduate School, School of Basic Medical Sciences, Fourth Military Medical University, Xi'an 710032, China
1b.
Department of Cell Biology, School of Basic Medical Sciences, Fourth Military Medical University, Xi'an 710032, China
2.
Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China

Research funding:

National Natural Science Foundation of China (82170667);

National Natural Science Foundation of China (81970566)

More Information

Corresponding author: TAO Kaishan, taokaishan0686@163.com(ORCID: 0000-0002-6038-4136)

摘要

摘要: 原发性肝癌具有恶性程度高、进展快、易复发转移和病死率高等特点，因此大多数患者就诊时已发生肝内或肝外转移，失去手术治疗机会。嵌合抗原受体T淋巴细胞(CAR-T)免疫疗法已在B细胞急性淋巴性白血病治疗中取得了较好的效果，其在原发性肝癌、胰腺癌、胃癌以及前列腺癌等实体瘤中的应用也陆续开展了临床试验。本文综述了CAR-T免疫疗法在原发性肝癌临床试验中的疗效，并讨论了其在临床应用中需攻克的难题，如缺乏适宜的肿瘤靶点、肿瘤微环境对CAR-T的抑制作用以及CAR-T对肿瘤组织的浸润性差等，以期为临床研究提供参考。
- 肝肿瘤 /
- 免疫疗法 /
- 嵌合抗原受体T淋巴细胞
Abstract: Primary liver cancer has the features of high malignancy, rapid progression, frequent recurrence/metastasis, and high mortality, and therefore, most patients have developed intrahepatic or extrahepatic metastasis when attending the hospital and thus lost the opportunity for surgical treatment. Chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved good efficacy in the treatment of B-cell acute lymphoblastic leukemia, and clinical trials have been initiated to explore its applications in solid tumors such as primary liver cancer, pancreatic cancer, gastric cancer, and prostate cancer. This article reviews the efficacy of CAR-T immunotherapy in the clinical trials for primary liver cancer and discusses the difficult issues that need to be solved in clinical practice, such as the lack of suitable tumor targets, the inhibitory effect of tumor microenvironment on CAR-T cells, and the poor infiltration of CAR-T cells in tumor tissue, so as to provide a reference for related clinical studies.
- Liver Neoplasms /
- Immunotherapy /
- Chimeric Antigen Receptor T Cell

HTML全文

参考文献(42)

[1]	LLOVET JM, ZUCMAN-ROSSI J, PIKARSKY E, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2016, 2: 16018. DOI: 10.1038/nrdp.2016.18.
[2]	SIEGEL RL, MILLER KD, FUCHS HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 71(1): 7-33. DOI: 10.3322/caac.21654.
[3]	DEMIR T, LEE SS, KASEB AO. Systemic therapy of liver cancer[J]. Adv Cancer Res, 2021, 149: 257-294. DOI: 10.1016/bs.acr.2020.12.001.
[4]	ZHONG JH, LI H, LI LQ, et al. Adjuvant therapy options following curative treatment of hepatocellular carcinoma: a systematic review of randomized trials[J]. Eur J Surg Oncol, 2012, 38(4): 286-295. DOI: 10.1016/j.ejso.2012.01.006.
[5]	LLOVET JM, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390. DOI: 10.1056/NEJMoa0708857.
[6]	GALON J, BRUNI D. Tumor immunology and tumor evolution: Intertwined histories[J]. Immunity, 2020, 52(1): 55-81. DOI: 10.1016/j.immuni.2019.12.018.
[7]	WALL DA, KRUEGER J. Chimeric antigen receptor T cell therapy comes to clinical practice[J]. Curr Oncol, 2020, 27(Suppl 2): s115-s123. DOI: 10.3747/co.27.5283.
[8]	HOSEN N. Chimeric antigen receptor T-cell therapy for multiple myeloma[J]. Int J Hematol, 2020, 111(4): 530-534. DOI: 10.1007/s12185-020-02827-8.
[9]	ROSELLI E, FARAMAND R, DAVILA ML. Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes[J]. J Clin Invest, 2021, 131(2): e142030. DOI: 10.1172/JCI142030.
[10]	KIM DW, CHO JY. Recent advances in allogeneic CAR-T cells[J]. Biomolecules, 2020, 10(2): 263. DOI: 10.3390/biom10020263.
[11]	ABRAMSON JS, MCGREE B, NOYES S, et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma[J]. N Engl J Med, 2017, 377(8): 783-784. DOI: 10.1056/NEJMc1704610.
[12]	O'ROURKE DM, NASRALLAH MP, DESAI A, et al. A single dose of peripherally infused EGFRvⅢ-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma[J]. Sci Transl Med, 2017, 9(399): eaaa0984. DOI: 10.1126/scitranslmed.aaa0984.
[13]	CADILHA BL, BENMEBAREK MR, DORMAN K, et al. Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors[J]. Sci Adv, 2021, 7(24): eabi5781. DOI: 10.1126/sciadv.abi5781.
[14]	WEI J, GUO Y, WANG Y, et al. Clinical development of CAR T cell therapy in China: 2020 update[J]. Cell Mol Immunol, 2021, 18(4): 792-804. DOI: 10.1038/s41423-020-00555-x.
[15]	WANG Y, CHEN M, WU Z, et al. CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial[J]. Oncoimmunology, 2018, 7(7): e1440169. DOI: 10.1080/2162402X.2018.1440169.
[16]	SHI D, SHI Y, KASEB AO, et al. Chimeric antigen receptor-glypican-3 T-cell therapy for advanced hepatocellular carcinoma: Results of phase I trials[J]. Clin Cancer Res, 2020, 26(15): 3979-3989. DOI: 10.1158/1078-0432.CCR-19-3259.
[17]	LIU H, XU Y, XIANG J, et al. Targeting alpha-fetoprotein (AFP)-MHC complex with CAR T-cell therapy for liver cancer[J]. Clin Cancer Res, 2017, 23(2): 478-488. DOI: 10.1158/1078-0432.CCR-16-1203.
[18]	LIM WA, JUNE CH. The principles of engineering immune cells to treat cancer[J]. Cell, 2017, 168(4): 724-740. DOI: 10.1016/j.cell.2017.01.016.
[19]	di STASI A, de ANGELIS B, ROONEY CM, et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model[J]. Blood, 2009, 113(25): 6392-6402. DOI: 10.1182/blood-2009-03-209650.
[20]	ZHANG RY, WEI D, LIU ZK, et al. Doxycycline inducible chimeric antigen receptor T cells targeting CD147 for hepatocellular carcinoma therapy[J]. Front Cell Dev Biol, 2019, 7: 233. DOI: 10.3389/fcell.2019.00233.
[21]	WANG JY, WANG XK, ZHU GZ, et al. Distinct diagnostic and prognostic values of Glypicans gene expression in patients with hepatocellular carcinoma[J]. BMC Cancer, 2021, 21(1): 462. DOI: 10.1186/s12885-021-08104-z.
[22]	THISTLETHWAITE FC, GILHAM DE, GUEST RD, et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity[J]. Cancer Immunol Immunother, 2017, 66(11): 1425-1436. DOI: 10.1007/s00262-017-2034-7.
[23]	WANG SJ, CHAO D, WEI W, et al. CD147 promotes collective invasion through cathepsin B in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2020, 39(1): 145. DOI: 10.1186/s13046-020-01647-2.
[24]	BIAN H, ZHENG JS, NAN G, et al. Randomized trial of[131I] metuximab in treatment of hepatocellular carcinoma after percutaneous radiofrequency ablation[J]. J Natl Cancer Inst, 2014, 106(9): dju239. DOI: 10.1093/jnci/dju239.
[25]	CHEN C, LI K, JIANG H, et al. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma[J]. Cancer Immunol Immunother, 2017, 66(4): 475-489. DOI: 10.1007/s00262-016-1949-8.
[26]	TANG XY, DING YS, ZHOU T, et al. Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors[J]. Cancer Lett, 2021, 503: 69-74. DOI: 10.1016/j.canlet.2021.01.014.
[27]	MIKUCKI ME, FISHER DT, MATSUZAKI J, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints[J]. Nat Commun, 2015, 6: 7458. DOI: 10.1038/ncomms8458.
[28]	ADACHI K, KANO Y, NAGAI T, et al. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor[J]. Nat Biotechnol, 2018, 36(4): 346-351. DOI: 10.1038/nbt.4086.
[29]	CHEN Y, YU Z, TAN X, et al. CAR-macrophage: A new immunotherapy candidate against solid tumors[J]. Biomed Pharmacother, 2021, 139: 111605. DOI: 10.1016/j.biopha.2021.111605.
[30]	WANG LC, LO A, SCHOLLER J, et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity[J]. Cancer Immunol Res, 2014, 2(2): 154-166. DOI: 10.1158/2326-6066.CIR-13-0027.
[31]	EGGERT T, GRETEN TF. Tumor regulation of the tissue environment in the liver[J]. Pharmacol Ther, 2017, 173: 47-57. DOI: 10.1016/j.pharmthera.2017.02.005.
[32]	MENG X, XU Y, NING X. Tumor microenvironment acidity modulates ROR1 to promote epithelial-mesenchymal transition and hepatocarcinoma metastasis[J]. J Cell Sci, 2021, 134(7): jcs255349. DOI: 10.1242/jcs.255349.
[33]	de HENAU O, RAUSCH M, WINKLER D, et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells[J]. Nature, 2016, 539(7629): 443-447. DOI: 10.1038/nature20554.
[34]	HÖCHST B, SCHILDBERG FA, BÖTTCHER J, et al. Liver sinusoidal endothelial cells contribute to CD8 T cell tolerance toward circulating carcinoembryonic antigen in mice[J]. Hepatology, 2012, 56(5): 1924-1933. DOI: 10.1002/hep.25844.
[35]	SACHDEVA M, DUCHATEAU P, DEPIL S, et al. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators[J]. J Biol Chem, 2019, 294(14): 5430-5437. DOI: 10.1074/jbc.AC119.007558.
[36]	NORELLI M, CAMISA B, BARBIERA G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells[J]. Nat Med, 2018, 24(6): 739-748. DOI: 10.1038/s41591-018-0036-4.
[37]	GUPTA S, SEETHAPATHY H, STROHBEHN IA, et al. Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma[J]. Am J Kidney Dis, 2020, 76(1): 63-71. DOI: 10.1053/j.ajkd.2019.10.011.
[38]	HARIRI G, JOFFRE J, DERYCKERE S, et al. Albumin infusion improves endothelial function in septic shock patients: a pilot study[J]. Intensive Care Med, 2018, 44(5): 669-671. DOI: 10.1007/s00134-018-5075-2.
[39]	MACKALL CL, MIKLOS DB. CNS endothelial cell activation emerges as a driver of CAR T cell-associated neurotoxicity[J]. Cancer Discov, 2017, 7(12): 1371-1373. DOI: 10.1158/2159-8290.CD-17-1084.
[40]	LEE DW, SANTOMASSO BD, LOCKE FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells[J]. Biol Blood Marrow Transplant, 2019, 25(4): 625-638. DOI: 10.1016/j.bbmt.2018.12.758.
[41]	VARADARAJAN I, LEE DW. Management of T-cell engaging immunotherapy complications[J]. Cancer J, 2019, 25(3): 223-230. DOI: 10.1097/PPO.0000000000000377.
[42]	CAO JX, WANG H, GAO WJ, et al. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma[J]. Cytotherapy, 2020, 22(4): 214-226. DOI: 10.1016/j.jcyt.2020.01.015.